To evaluate the mental health status, specifically anxiety and depression levels, of NSCLC patients and assess the impact of tandospirone on emotional distress and chemotherapy efficacy.
Key Findings:
32.2% of postoperative NSCLC patients experienced emotional distress compared to 8.9% in healthy controls, highlighting the need for targeted interventions.
Chemotherapy was identified as a significant independent risk factor for increased emotional distress in NSCLC patients, necessitating integrated treatment approaches.
Tandospirone was found to lower cholesterol levels in tumor cells, enhancing their susceptibility to apoptosis and improving chemotherapy response, suggesting a potential dual role in treatment.
Interpretation:
Systematic management of emotional distress is crucial in lung cancer care, and tandospirone presents a dual benefit of alleviating psychological symptoms while enhancing the efficacy of chemotherapy, thus supporting a more holistic treatment approach.
Limitations:
The study did not include patients with pre-existing psychiatric disorders or those currently on anti-ED medications, which may limit the generalizability of the findings.
The long-term effects of tandospirone on tumor progression and patient outcomes require further investigation to fully understand its therapeutic potential.
Conclusion:
Tandospirone may serve as a promising adjunct therapy in NSCLC treatment, addressing both emotional distress and enhancing chemotherapy efficacy.
